Exposure to endogenous sex hormones has been reported as a risk factor for breast cancer. The CYP11A1 gene encodes the key enzyme that catalyzes the initial and rate-limiting step in steroid hormone synthesis. In this study, the associations between single nucleotide polymorphisms (SNPs) in CYP11A1 and breast cancer susceptibility were examined. Six SNPs in CYP11A1 were genotyped using the MassARRAY IPLEX platform in 530 breast cancer patients and 546 healthy controls. Association analyses based on a χ 2 test and binary logistic regression were performed to determine the odds ratio ( OR) and 95% confidence interval (95% CI) for each SNP. Two loci (rs2959008 and rs2279357) showed evidence of associations with breast cancer risk. The variant genotype C/T-C/C of rs2959008 was significantly associated with a decreased risk (age-adjusted OR, 0.75; 95% CI, 0.58–0.96; P = 0.023) compared with the wild-type TT. However, the homozygous TT variant of rs2279357 exhibited increased susceptibility to breast cancer (age-adjusted OR, 1.44; 95% CI, 1.05–1.98; P = 0.022). The locus rs2959003 also showed an appreciable effect, but no associations were observed for three other SNPs. Our results suggest that polymorphisms of CYP11A1 are related to breast cancer susceptibility in Han Chinese women of South China.
References
[1]
Leong, S.P.; Shen, Z.Z.; Liu, T.J.; Agarwal, G.; Tajima, T.; Paik, N.S.; Sandelin, K.; Derossis, A.; Cody, H.; Foulkes, W.D. Is breast cancer the same disease in Asian and Western countries? World J. Surg 2010, 34, 2308–2324.
[2]
Mavaddat, N.; Antoniou, A.C.; Easton, D.F.; Garcia-Closas, M. Genetic susceptibility to breast cancer. Mol. Oncol 2010, 4, 174–191.
[3]
Begg, C.B.; Haile, R.W.; Borg, A.; Malone, K.E.; Concannon, P.; Thomas, D.C.; Langholz, B.; Bernstein, L.; Olsen, J.H.; Lynch, C.F.; et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008, 299, 194–201.
[4]
Campeau, P.M.; Foulkes, W.D.; Tischkowitz, M.D. Hereditary breast cancer: New genetic developments, new therapeutic avenues. Hum. Genet 2008, 124, 31–42.
[5]
CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9065 controls from 10 studies. Am. J. Hum. Genet 2004, 74, 1175–1182.
[6]
Rahman, N.; Seal, S.; Thompson, D.; Kelly, P.; Renwick, A.; Elliott, A.; Reid, S.; Spanova, K.; Barfoot, R.; Chagtai, T.; et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet 2007, 39, 165–167.
[7]
Seal, S.; Thompson, D.; Renwick, A.; Elliott, A.; Kelly, P.; Barfoot, R.; Chagtai, T.; Jayatilake, H.; Ahmed, M.; Spanova, K.; et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet 2006, 38, 1239–1241.
[8]
King, M.C.; Marks, J.H.; Mandell, J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302, 643–646.
[9]
Fletcher, O.; Johnson, N.; Orr, N.; Hosking, F.J.; Gibson, L.J.; Walker, K.; Zelenika, D.; Gut, I.; Heath, S.; Palles, C.; et al. Novel breast cancer susceptibility locus at 9q31.2: Results of a genome-wide association study. J. Nat. Cancer Inst 2011, 103, 425–435.
[10]
Li, J.; Humphreys, K.; Heikkinen, T.; Aittom？ki, K.; Blomqvist, C.; Pharoah, P.D.; Dunning, A.M.; Ahmed, S.; Hooning, M.J.; Martens, J.W.; et al. A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res. Treat 2011, 126, 717–727.
[11]
Long, J.; Cai, Q.; Sung, H.; Shi, J.; Zhang, B.; Choi, J.Y.; Wen, W.; Delahanty, R.J.; Lu, W.; Gao, Y.T.; et al. Genome-wide association study in East asians identifies novel susceptibility Loci for breast cancer. PLoS Genet 2012, 8, doi:10.1371/journal.pgen.1002532.
[12]
Turnbull, C.; Ahmed, S.; Morrison, J.; Pernet, D.; Renwick, A.; Maranian, M.; Seal, S.; Ghoussaini, M.; Hines, S.; Healey, C.S.; et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat. Genet 2010, 42, 504–507.
[13]
Thomas, G.; Jacobs, K.B.; Kraft, P.; Yeager, M.; Wacholder, S.; Cox, D.G.; Hankinson, S.E.; Hutchinson, A.; Wang, Z.; Yu, K.; et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet 2009, 41, 579–584.
[14]
Key, T.; Appleby, P.; Barnes, I.; Reeves, G. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J. Nat. Cancer Inst 2002, 94, 606–616.
[15]
Folkerd, E.J.; Martin, L.A.; Kendall, A.; Dowsett, M. The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. J. Steroid Biochem. Mol. Biol 2006, 102, 250–255.
[16]
Sakoda, L.C.; Blackston, C.; Doherty, J.A.; Ray, R.M.; Lin, M.G.; Stalsberg, H.; Gao, D.L.; Feng, Z.; Thomas, D.B.; Chen, C. Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Cancer Epidem. Biomarker. Prev 2008, 17, 1066–1073.
[17]
Zheng, W.; Gao, Y.T.; Shu, X.O.; Wen, W.; Cai, Q.; Dai, Q.; Smith, J.R. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidem. Biomarker. Prev 2004, 13, 709–714.
[18]
Setiawan, V.W.; Cheng, I.; Stram, D.O.; Giorgi, E.; Pike, M.C.; Van den Berg, D.; Pooler, L.; Burtt, N.P.; Le Marchand, L.; Altshuler, D.; et al. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer. Cancer Res 2006, 66, 12019–12025.
[19]
Yaspan, B.L.; Breyer, J.P.; Cai, Q.; Dai, Q.; Elmore, J.B.; Amundson, I.; Bradley, K.M.; Shu, X.O.; Gao, Y.T.; Dupont, W.D.; et al. Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk. Cancer Res 2007, 67, 5673–5682.
[20]
Payne, A.H.; Hales, D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev 2004, 25, 947–970.
[21]
Gao, G.H.; Cao, Y.X.; Yi, L.; Wei, Z.L.; Xu, Y.P.; Yang, C. Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome. Chin. J. Obstet. Gynecol 2010, 45, 191–196.
[22]
Celhar, T.; Gersak, K.; Ovcak, Z.; Sedmak, B.; Mlinaric-Rascan, I. The presence of the CYP11A1 (TTTTA)6 allele increases the risk of biochemical relapse in organ confined and low-grade prostate cancer. Cancer Genet. Cytogenet 2008, 187, 28–33.
[23]
Kumazawa, T.; Tsuchiya, N.; Wang, L.; Sato, K.; Kamoto, T.; Ogawa, O.; Nakamura, A.; Kato, T.; Habuchi, T. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int. J. Cancer 2004, 110, 140–144.
[24]
Terry, K.; McGrath, M.; Lee, I.M.; Buring, J.; de Vivo, I. Genetic variation in CYP11A1 and StAR in relation to endometrial cancer risk. Gynecol. Oncol 2010, 117, 255–259.
Boyd, N.F.; Martin, L.J.; Yaffe, M.J.; Minkin, S. Mammographic density: A hormonally responsive risk factor for breast cancer. J. Br. Menopause Soc 2006, 12, 186–193.
[27]
Li, J.; Eriksson, L.; Humphreys, K.; Czene, K.; Liu, J.; Tamimi, R.M.; Lindstr？m, S.; Hunter, D.J.; Vachon, C.M.; Couch, F.J.; et al. Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. Breast Cancer Res 2010, 12, doi:10.1186/bcr2488.
[28]
Miyaki, K.; Htun, N.C.; Song, Y.; Ikeda, S.; Muramatsu, M.; Shimbo, T. The combined impact of 12 common variants on hypertension in Japanese men, considering GWAS results. J. Hum. Hypertension, 2011. Available online: http://www.nature.com/jhh/journal/vaop/ncurrent/abs/jhh201150a.html , accessed on 23 March 2012.
[29]
Solé, X.; Guinó, E.; Valls, J.; Iniesta, R.; Moreno, V. SNPStats: A web tool for the analysis of association studies. Bioinformatics 2006, 22, 1928–1929.
